Electrical stimulation to relieve chemotherapy-related nerve pain in breast cancer patients
The Efficacy of Social Media Assisted Home-based Transcutaneous Electrical Acupoint Stimulation on Symptoms Associated with Chemotherapy Induced Peripheral Neuropathy in Patients with Breast Cancer
This study is testing whether a special electrical treatment can help breast cancer patients who have nerve pain from chemotherapy feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 86 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | National Taipei University of Nursing and Health Sciences Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Changhua, Changhua) |
| Trial ID | NCT05904340 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of transcutaneous electrical acupoint stimulation on alleviating symptoms of chemotherapy-induced peripheral neuropathy in breast cancer patients. It will recruit 86 patients who have recently completed chemotherapy and are experiencing nerve-related symptoms. Participants will be randomly assigned to either the stimulation group, receiving the intervention for four weeks, or a control group with no treatment. Data will be collected at multiple time points to assess the effectiveness of the intervention.
Who should consider this trial
Good fit: Ideal candidates are breast cancer patients who have completed chemotherapy within the last three months and are experiencing moderate to severe peripheral neuropathy.
Not a fit: Patients with stage IV cancer, metastatic disease, or those currently on neuropathy medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life for breast cancer patients suffering from chemotherapy-induced peripheral neuropathy.
How similar studies have performed: While there is limited data on this specific approach, similar studies using electrical stimulation for neuropathy have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Primary diagnosed with breast cancer for the first time by a physician. 2. Patients who have completed chemotherapy or postoperative adjuvant chemotherapy within 3 months, and the chemotherapy drugs used are paclitaxel, vinblastine or platinum drugs. 3. Patients who have been evaluated by doctors as peripheral neuropathy caused by chemotherapy, and whose symptoms persist after completing chemotherapy. 4. Peripheral sensory or peripheral motor neuropathy grade ≥ 2 in general toxicity criteria (NCI-CTCAE). 5. Those who have clear consciousness and can communicate in Mandarin or Taiwanese. Exclusion Criteria: 1. Patients suffering from carcinoma in situ. 2. Patients suffering from stage IV cancer. 3. Patients suffering from metastatic cancer. 4. Patients receiving peripheral neuropathy drugs (Duloxetine) 5. Patients receiving acupoint stimulation therapy. 6. Patients who are allergic to silicone patches. 7. Patients with cardiac pacemakers. 8. Patients suffering from diabetic peripheral neuropathy. 9. Patients suffering from peripheral neuropathy of acquired immunodeficiency syndrome. 10. Patients receiving treatment for mental illness.
Where this trial is running
Changhua, Changhua
- Changhua Christian Hospital — Changhua, Changhua, Taiwan (Recruiting)
Study contacts
- Principal investigator: Wang, Phd — National Taipei University of Nursing and Health Sciences
- Study coordinator: Chia Hao Yang
- Email: henry1993110101@gmail.com
- Phone: +886912631133
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.